Abstract
Patients with oligometastatic disease can benefit from local treatment of the metastases. Under these premises the resection of liver metastases and visceral metastases of non-gastrointestinal tumors is performed increasingly more frequently in selected patients. The aim of this study was to evaluate the role of visceral oncological surgery in hepatic oligometastatic disease of non-gastrointestinal tumors according to the currently available literature. A systematic search of MEDLINE and PubMed was carried out focusing on the topics of oligometastases, liver resection and metastectomy for breast cancer, renal cell carcinoma, malignant melanoma, ovarian cancer and non-small cell lung cancer. The evidence is limited to retrospective studies and case series. In selected patients after liver resection and multimodal therapy 5‑year survival rates of 53% (breast cancer), 62% (renal cell carcinoma), 22% (malignant melanoma) and 50% (ovarian cancer) are described. For lung cancer (NSCLC) median survival was 12 month. Prognostic factors n were a disease free survival of >12 months, R0-resection, response to systemic therapy and extra hepatic/extra abdominal metastases. These could be selection criteria for liver resection. Recurrence li...Continue Reading
References
Nov 24, 2006·Annals of Surgery·René AdamDenis Castaing
Mar 14, 2007·World Journal of Surgery·Armin ThelenP Neuhaus
Feb 4, 2009·Cancer·Andreas du BoisJacobus Pfisterer
Mar 31, 2009·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·P MarianiR J Salmon
May 5, 2010·World Journal of Urology·Michael D StaehlerChristiane J Bruns
Dec 7, 2010·Archives of Gynecology and Obstetrics·Hyun-Jin RohJoo-Hyun Nam
Mar 20, 2012·Journal of the American College of Surgeons·Ryan T GroeschlT Clark Gamblin
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F CardosoUNKNOWN ESMO Guidelines Working Group
Jun 19, 2013·The British Journal of Surgery·J-M AubinG Martel
Aug 26, 2014·Langenbeck's Archives of Surgery·Timothy L FitzgeraldEmmanuel E Zervos
Dec 3, 2014·The Lancet Oncology·Saeed DabestaniAxel Bex
Jan 27, 2015·European Urology·Borje LjungbergAxel Bex
Oct 8, 2015·Annals of Surgery·Eran SadotMichael I D'Angelica
Apr 12, 2016·PloS One·Paolo GrassiGiuseppe Procopio
Jul 30, 2016·Current Opinion in Urology·Saeed DabestaniAxel Bex
Aug 4, 2016·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·Georgios A MargonisTimothy M Pawlik
Oct 30, 2016·The Lancet Oncology·Daniel R GomezJohn V Heymach
Feb 15, 2017·The Breast : Official Journal of the European Society of Mastology·Tae Gon YooAdam Bartlett
Jun 3, 2017·Breast Cancer Research and Treatment·Tae-Kyung YooByung Joo Song
Jun 8, 2017·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Thomas K EigentlerClaus Garbe
Aug 31, 2017·The New England Journal of Medicine·Martin Reck, Klaus F Rabe
Dec 11, 2017·European Urology·Thomas PowlesAxel Bex
Jan 13, 2018·Journal of Oncology Practice·Sarah Jo StephensJoseph K Salama
Jan 18, 2018·The New England Journal of Medicine·Willemien J van DrielGabe S Sonke
Feb 3, 2018·Irish Journal of Medical Science·Sadia TasleemCarmel Malone
Mar 8, 2018·International Journal of Clinical Oncology·Fumitaka IshigeYosuke Iwatate